TL;DR
Get oils, diffusers and self-care delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A study published in the Journal of Experimental Medicine found that pantethine reduced psoriasis-like inflammation in mice and was associated with greater symptom improvement in a 24-person patient trial when added to topical treatment. The early results do not establish pantethine as an effective standalone treatment or confirm the mechanism in people; larger studies are needed.
Pantethine, a widely available supplement derived from vitamin B5, was associated with greater improvement in psoriasis symptoms when added to prescribed topical treatment in a small clinical trial, researchers reported in a study published October 27 in the Journal of Experimental Medicine. The results, from 24 patients and supporting experiments in mice, are preliminary and do not show that the supplement can treat psoriasis on its own.
All 24 participants in the trial received an ointment containing calcipotriene and betamethasone, medicines used to manage psoriasis. Half also took pantethine tablets. After 12 weeks, the group taking pantethine showed greater improvement in symptoms, according to the study. Researchers said the difference was especially noticeable among participants who had high blood cholesterol before treatment.
The trial was small, and the report does not establish how large or durable the added benefit was. The researchers also said the patient results do not confirm that the biological mechanism observed in laboratory experiments caused the improvements. The study presents pantethine as a possible adjunct to standard treatment, not a replacement for prescribed care.
In experiments, the team found elevated levels of enzymes called Vanins in dendritic cells from people with psoriasis and several other autoimmune diseases. These immune cells help direct responses involving T cells. In mice, reducing Vanin activity or giving pantethine limited immune-cell activation and psoriasis-like disease, the researchers reported.
A Possible Add-On to Topical Care
The findings point to a possible connection between cell metabolism and immune inflammation in psoriasis. If larger trials confirm the patient results, pantethine could be studied as an addition to existing therapies, including for people with elevated cholesterol. That possibility matters because the trial tested the supplement alongside a treatment patients already received, rather than as a substitute.
For now, the evidence is not enough to guide treatment decisions. A 24-person study can identify a signal worth testing, but it cannot reliably establish how well the supplement works across a wider population or which patients might benefit. People with psoriasis should not stop or alter prescribed treatment based on these findings; supplement use should be discussed with a health professional.
Products Worth Considering
Therabody JetBoots Prime Wireless Compression Boots – Regular 30-34 Inseam
Levoit Vital 100S-P Smart Air Purifier with Washable Pre-Filter
Therabody SmartGoggles 2nd Gen Heated Eye and Temple Massager
As an affiliate, we earn on qualifying purchases.
How Vanins Connect to Cholesterol
The researchers propose that Vanin activity affects the amount of pantethine available inside dendritic cells. Vanins convert pantethine into vitamin B5, which cells use in energy-related processes. The team found that lower pantethine availability was linked in its experiments to increased cholesterol production inside those cells and greater immune activity.
Pantethine is already sold as a nutritional supplement and is commonly used in attempts to lower blood cholesterol. The study focuses on a different proposed role: reducing cholesterol accumulation within immune cells. The authors reported that restoring pantethine levels reduced this accumulation and dampened excessive immune activation in their laboratory work.
Senior researcher Wei-Na Zhang and colleagues from research institutions in Beijing conducted the work. The study also included a small investigator-initiated clinical trial. Its results support further research into the proposed Vanin-pantethine-cholesterol pathway, but do not prove that the same pathway explains psoriasis or the patients’ response.
What the Small Trial Cannot Show
The human trial included only 24 participants and lasted 12 weeks. The report does not provide enough information to establish whether the apparent added benefit would persist, how it compares across different patient groups, or what dose and duration would be appropriate. It also does not show whether pantethine would help people who do not have high cholesterol.
The study’s patient results do not prove that changes in cholesterol production within dendritic cells drove the symptom improvement. The researchers said larger studies are needed to confirm effectiveness. The supplied report also does not provide detailed adverse-event findings, so the results should not be read as establishing the supplement’s safety for psoriasis treatment.
Larger Trials Are the Next Test
The researchers say larger clinical studies are needed to test whether pantethine adds a reliable benefit to standard psoriasis treatment. Further research would need to clarify the size and durability of any improvement, identify which patients might benefit, and assess safety and dosing.
Until those results are available, pantethine remains a research lead rather than an established psoriasis therapy. Patients should continue to follow their clinician’s treatment plan and consult a health professional before adding a supplement, particularly if they have other health conditions or take medication.
Key Questions
Does this study show pantethine cures psoriasis?
No. The study reported early results from a small trial in which pantethine was added to prescribed topical treatment. It did not test the supplement as a cure or as a standalone therapy.
How many people took part in the human trial?
Twenty-four patients took part. All used calcipotriene/betamethasone ointment, and half also took pantethine tablets.
How long did the trial last?
Participants were followed for 12 weeks. The study does not establish whether any improvement lasts beyond that period.
Should people with psoriasis start taking pantethine?
The findings are preliminary and do not establish pantethine as a psoriasis treatment. People should not change prescribed care based on this study and should discuss supplement use with a health professional.
Source: sciencedaily.com
